Immune checkpoints (ICs) play a pivotal role in orchestrating immune regulation, crucial for the maintenance of immune tolerance and prevention of autoimmune diseases. One noteworthy example among these immune regulators is T cell immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT). The TIGIT pathway’s inhibition or the absence of TIGIT has been linked to the hyperactivation and excessive proliferation of T cells, rendering individuals more susceptible to autoimmune diseases and exacerbating inflammatory responses. Conversely, the activation of TIGIT has exhibited promising outcomes in ameliorating autoimmune disorders, as observed in murine models of systemic lupus erythematosus (SLE). Consequently, a judicious exploration of the co-inhibitory axis appears warranted for the effective management of pathogenic immune responses in SLE. In light of compelling evidence, this review undertakes a comprehensive examination of TIGIT’s characteristics within the context of autoimmunity, offering insights into its potential as a therapeutic target for SLE.
YuXHardenKGonzalezLC, et al.The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol2009; 10: 48–57.
2.
AndersonACJollerNKuchrooVK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity2016; 44: 989–1004.
3.
PaukenKEWherryEJ. TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit. Cancer Cell2014; 26: 785–787.
MoultonVRSuarez-FueyoAMeidanE, et al.Pathogenesis of human systemic lupus erythematosus: a cellular perspective. Trends Mol Med2017; 23: 615–635.
6.
JollerNPetersAAndersonAC, et al.Immune checkpoints in central nervous system autoimmunity. Immunol Rev2012; 248: 122–139.
7.
EdnerNMCarlessoGRushJS, et al.Targeting co-stimulatory molecules in autoimmune disease. Nat Rev Drug Discov2020; 19: 860–883.
8.
LiuSSunLWangC, et al.Treatment of murine lupus with TIGIT-Ig. Clin Immunol2019; 203: 72–80.
9.
ZhaoJLiLFengX, et al. TIGIT-Fc fusion protein alleviates murine lupus nephritis through the regulation of SPI-B-PAX5-XBP1 axis-mediated B-cell differentiation. J Autoimmun2023; 139: 103087.
10.
KojimaMSuzukiKTakeshitaM, et al.Anti-human-TIGIT agonistic antibody ameliorates autoimmune diseases by inhibiting Tfh and Tph cells and enhancing Treg cells. Commun Biol2023; 6: 500.
11.
CatakovicKGassnerFJRatswohlC, et al.TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. OncoImmunology2017; 7: Article e1371399.
12.
FuhrmanCAYehWISeayHR, et al.Divergent phenotypes of human regulatory T cells expressing the receptors TIGIT and CD226. J Immunol2015; 195: 145–155.
13.
BolesKSVermiWFacchettiF, et al.A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol2009; 39: 695–703.
14.
LiuXYaoJZhaoY, et al.Heterogeneous plasma cells and long-lived subsets in response to immunization, autoantigen and microbiota. Nat Immunol2022; 23: 1564–1576.
15.
MauriCBosmaA. Immune regulatory function of B cells. Annu Rev Immunol2012; 30: 221–241.
16.
YamadaTTatematsuMTakasugaS, et al.TIGIT mediates activation-induced cell death of ILC2s during chronic airway allergy. J Exp Med2023; 220: Article e20222005.
17.
RudakPTGangireddyRChoiJ, et al.Stress-elicited glucocorticoid receptor signaling upregulates TIGIT in innate-like invariant T lymphocytes. Brain Behav Immun2019; 80: 793–804.
18.
BrauneckFFischerBWittM, et al.TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis. J Immunother Cancer2022; 10: Article e004794.
19.
ZhangBZhaoWLiH, et al.Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155. Cancer Immunol Immunother2016; 65: 305–314.
20.
KaitoYSugimotoENakamuraF, et al.DNAM-1/Tigit/CD155/CD112 Axis is a novel target of NK-cell therapy in acute myeloid leukemia. Blood2022; 140: 4514–4516.
21.
QiuDLiuXWangW, et al.Tigit axis: novel immune checkpoints in anti-leukemia immunity. Clin Exp Med2023; 23: 165–174.
22.
Kučan BrlićPLenac RovišTCinamonG, et al.Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol2019; 16: 40–52.
23.
StanietskyNSimicHArapovicJ, et al.The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A2009; 106: 17858–17863.
24.
MendelsohnCLWimmerERacanielloVR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell1989; 56: 855–865.
25.
KrausAKChenJEdenhoferI, et al.The role of T cell costimulation via DNAM-1 in kidney transplantation. PLoS One2016; 11: Article e0147951.
26.
LiAJiBYangY, et al.Single-cell RNA sequencing highlights the role of PVR/PVRL2 in the immunosuppressive tumour microenvironment in hepatocellular carcinoma. Front Immunol2023; 14: 1164448.
27.
JinH-sParkY. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy. BMB Rep2021; 54: 2–11.
28.
M-RabetMCabaudOJosselinE, et al.Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Ann Oncol2017; 28: 769–776.
29.
KoshkinVSHendersonNJamesM, et al. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. 2022; 128: 1194–1205.
30.
HeathEIRosenbergJE. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol2021; 18: 93–103.
31.
NishiwadaSShoMYasudaS, et al.Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res2015; 34: 30.
32.
AbedJEmgårdJEZamirG, et al.Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe2016; 20: 215–225.
33.
BottinoCCastriconiRPendeD, et al.Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med2003; 198: 557–567.
34.
ZhuYPanicciaASchulickAC, et al.Identification of CD112R as a novel checkpoint for human T cells. J Exp Med2016; 213: 167–176.
35.
ZengTCaoYJinT, et al.The CD112R/CD112 axis: a breakthrough in cancer immunotherapy. J Exp Clin Cancer Res2021; 40: 285.
36.
WhelanSOphirEKotturiMF, et al.PVRIG and PVRL2 are induced in cancer and inhibit CD8(+) T-cell function. Cancer Immunol Res2019; 7: 257–268.
37.
StengelKFHarden-BowlesKYuX, et al.Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering. Proc Natl Acad Sci U S A2012; 109: 5399–5404.
38.
LiuSZhangHLiM, et al.Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ2013; 20: 456–464.
39.
LiuLYouXHanS, et al.CD155/TIGIT, a novel immune checkpoint in human cancers (review). Oncol Rep2021; 45: 835–845.
40.
FathiMPustokhinaIKuznetsovSV, et al.T‐cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. IUBMB Life2021; 73: 726–738.
41.
DougallWCKurtulusSSmythMJ, et al.TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev2017; 276: 112–120.
42.
ShibuyaKShirakawaJKameyamaT, et al.CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J Exp Med2003; 198: 1829–1839.
43.
LozanoEJollerNCaoY, et al.The CD226/CD155 interaction regulates the proinflammatory (Th1/Th17)/anti-inflammatory (Th2) balance in humans. J Immunol2013; 191: 3673–3680.
44.
LozanoEDominguez-VillarMKuchrooV, et al.The TIGIT/CD226 axis regulates human T cell function. J Immunol2012; 188: 3869–3875.
45.
LozanoEDominguez-VillarMKuchrooV, et al.The TIGIT/CD226 axis regulates human T cell function. J Immunol2012; 188: 3869–3875.
46.
JollerNLozanoEBurkettPR, et al.Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity2014; 40: 569–581.
47.
LuccaLEAxisaP-PSingerER, et al.TIGIT signaling restores suppressor function of Th1 Tregs. JCI insight2019; 4: Article e124427.
48.
LuccaLEAxisaPPSingerER, et al.TIGIT signaling restores suppressor function of Th1 Tregs. JCI Insight2019; 4: Article e124427.
49.
ChiangEYMellmanI. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer2022; 10: Article e004711.
50.
ZhaoJLiLYinH, et al.TIGIT: an emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer. Int Immunopharm2023; 120: 110358.
51.
MaierMKSethSCzelothN, et al.The adhesion receptor CD155 determines the magnitude of humoral immune responses against orally ingested antigens. Eur J Immunol2007; 37: 2214–2225.
52.
WuHChenYLiuH, et al.Follicular regulatory T cells repress cytokine production by follicular helper T cells and optimize IgG responses in mice. Eur J Immunol2016; 46: 1152–1161.
53.
LuoQYeJZengL, et al.Elevated expression of TIGIT on CD3(+)CD4(+) T cells correlates with disease activity in systemic lupus erythematosus. Allergy Asthma Clin Immunol2017; 13: 15.
54.
MaoLHouHWuS, et al.TIGIT signalling pathway negatively regulates CD4(+) T-cell responses in systemic lupus erythematosus. Immunology2017; 151: 280–290.
55.
ZhouHLiBLiJ, et al.Dysregulated T cell activation and aberrant cytokine expression profile in systemic lupus erythematosus. Mediat Inflamm2019; 2019: 8450947.
56.
PanYTanMSuJ, et al.Significance of TIGIT in peripheral blood CD4 + T cells, and PD-L2 in monocytes in patients with systemic lupus erythematosus. Acta Med Mediterr2019; 35: 1079–1083.
57.
LuoQHuangZYeJ, et al.PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus. Arthritis Res Ther2016; 18: 47.
58.
LuoQLiXFuB, et al.Decreased expression of TIGIT in NK cells correlates negatively with disease activity in systemic lupus erythematosus. Int J Clin Exp Pathol2018; 11: 2408–2418.
59.
WangFHouHWuS, et al.TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals. Eur J Immunol2015; 45: 2886–2897.
60.
JiaBZhaoCRakszawskiKL, et al.Eomes(+)T-bet(low) CD8(+) T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia. Cancer Res2019; 79: 1635–1645.
61.
ZhangYMaksimovicJNaselliG, et al.Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T cells. Blood2013; 122: 2823–2836.
62.
TsaiHIWuYLiuX, et al.Engineered small extracellular vesicles as a FGL1/PD-L1 dual-targeting delivery system for alleviating immune rejection. Adv Sci2022; 9: Article e2102634.
63.
SodsaiPIttiwutCRuenjaimanV, et al.TIGIT monoallelic nonsense variant in patient with severe COVID-19 infection, Thailand. Emerg Infect Dis2022; 28: 2350–2352.
64.
ZhangHGuoJZhangQ, et al.The potential value of the neutrophil to lymphocyte ratio for early differential diagnosis and prognosis assessment in patients with aortic dissection. Biosci Rep2021; 97: 41–47.
65.
GuoQChenCWuZ, et al.Engineered PD-1/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell/Treg balance and alleviate systemic lupus erythematosus. Biomaterials2022; 285: 121517.
